Thrombolytic therapy for myocardial infarction.
Thrombolytic therapy has provided a practical means of reducing infarct size and infarct-related mortality. Clinicians must weigh the apparent risks and benefits of thrombolytic therapy: if the ischemic region is large, if treatment can be applied early enough to salvage ischemic myocardium, and if there is no obvious risk of life-threatening hemorrhage, it is likely the patient will benefit from thrombolytic therapy.
Guerci
A D
AD
Johns Hopkins Medical Institutions, Baltimore.
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D001241:Aspirin